Synergistic Effect Not Demonstrated in Final Analysis

NCT03409432 was a single-arm Phase 2 trial conducted in the United States by the Ohio State University Comprehensive Cancer Center, enrolling 26 patients with relapsed/refractory cutaneous T-cell lymphoma (CTCL) and peripheral T-cell lymphoma (PTCL). Adcetris (brentuximab vedotin) was administered intravenously at 1.2 mg/kg every three weeks, and Revlimid (lenalidomide) was administered orally from days 1 to 21; the dose was reduced from 20 mg to 10 mg due to tolerability issues. The trial was terminated early due to poor enrollment, failing to reach the planned number of participants, but the final data analysis was completed. The key takeaway is that, beyond the completion of the clinical trial itself, patient recruitment and the heterogeneity of histological subtypes limited the development speed in rare T-cell lymphomas.

PTCL Response Rate of 50%, CTCL of 27.8%

The patients were a heavily pre-treated group, with a median of 4.5 prior therapies, and included 8 PTCL patients and 18 CTCL patients in the efficacy analysis. Complete response (CR) was observed in 5 patients, and partial response (PR) in 4 patients, resulting in an overall response rate (ORR) of 50% for PTCL and 27.8% for CTCL. Grade 3 or higher adverse events occurred in 19 of the 26 patients, with the most common severe toxicity being neutropenia (19.2%). Progression was observed in 54%, and adverse events in 23%, which were the main reasons for treatment discontinuation. The researchers concluded that the efficacy was not significantly superior to that of the individual agents alone and that a basis for proceeding directly to a randomized, controlled Phase 3 trial was not established.

Limitations of CD30-Targeted ADC and Cereblon Modulator

Adcetris (brentuximab vedotin) is an antibody-drug conjugate (ADC) that combines an anti-CD30 antibody with the microtubule-disrupting agent MMAE, and the rights are currently held by Seagen, which was acquired by Pfizer (PFE), and Takeda Pharmaceutical (4502) as a partner outside of the United States and Canada. Revlimid (lenalidomide) is an immunomodulatory drug (IMiD) from Bristol Myers Squibb (BMY) that binds to cereblon, inducing degradation of transcription factors and immune regulation. This trial did not require CD30 positivity, and the average CD30 expression rate was only 7.5%, with 4 patients being CD30-negative, which diluted the target-dependent effect of the ADC. The broad enrollment strategy, which did not select for CD30 expression and histological subtypes, negatively impacted the verification of synergistic effects in the combination therapy.

Approved Product, but Combination Therapy Development Terminated

Adcetris was first approved by the FDA on August 19, 2011, for relapsed systemic anaplastic large cell lymphoma, and the indication was expanded on November 16, 2018, to include CHP combination therapy for CD30-positive, previously untreated PTCL. The EMA granted conditional approval on October 25, 2012, and converted it to full approval on May 24, 2022. Japan added the indication for CD30-positive PTCL on December 20, 2019, but there was no FDA AdComm vote or approval for this Adcetris and Revlimid combination therapy in T-cell lymphoma. Competing treatments include Adcetris alone or CHP, pralatrexate (Polivy), belinostat (Beleodaq), and bendamustine with hematopoietic stem cell transplantation for PTCL, and mogamulizumab (Poteligeo), vorinostat (Zolinza), and methotrexate for CTCL. The major 7-country PTCL market was estimated at $637.1 million in 2024, but this combination failed to establish a comparative advantage or a subsequent confirmatory development pathway.